{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T17:47:54Z","timestamp":1785779274675,"version":"3.56.0"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005725","name":"CHDI Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012068","name":"Health Care Research Wales","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012068","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009575","name":"Jacques and Gloria Gossweiler Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009575","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000866","name":"Cardiff University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000866","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Psychiatric symptoms are very common in Huntington\u2019s disease. In keeping with other neurodegenerative diseases, there are concerns that antidepressants might worsen disease progression. Previous work on antidepressant effects in Huntington\u2019s disease has been limited by confounding by indication, small sample sizes, short follow-up or a combination of these. We leveraged data from the ENROLL-HD (25 550 participants) cohort to determine whether symptoms associated with antidepressant initiation are associated with faster disease progression and whether antidepressants have an impact on disease progression and mortality in people with Huntington\u2019s disease experiencing these symptoms.<\/jats:p>\n                  <jats:p>Initially, we determined the commonest indications for antidepressant prescription in people with Huntington\u2019s disease. We selected adults with Huntington\u2019s disease (age \u226518 years, with genetically confirmed Huntington\u2019s disease), not on antidepressants and free of antidepressant-indication symptoms at baseline (n = 6166) and used linear mixed models to determine the association between symptoms listed as indications for antidepressant prescription and disease progression and mortality. Using propensity score weighting, we selected adults with Huntington\u2019s disease who remained antidepressant naive until an episode of antidepressant-indication symptoms (n = 1877) and compared disease progression and mortality between those starting an antidepressant (n = 194) before the next follow-up versus those who did not (n = 1683). Outcomes were disease progression, measured by the composite disease score in ENROLL-HD, and mortality.<\/jats:p>\n                  <jats:p>Depression and anxiety accounted for &amp;gt;80% of indications for antidepressant prescription in people with Huntington\u2019s disease: episodes of depression\/anxiety (experienced by 3131\/6166) were associated with increased composite disease score progression from 0.46 to 0.52\/year (P = 3.1 \u00d7 10\u221211) and increased mortality (hazard ratio = 1.5, P = 9.4 \u00d7 10\u22126). In people with Huntington\u2019s disease with new depression\/anxiety free of antidepressants at symptom onset, antidepressant initiation (n = 194\/1877) reduced composite disease score decline from 0.89 to 0.53\/year (P = 0.002) and reduced all-cause mortality (hazard ratio = 0.38, P = 0.04). An exploratory analysis of antidepressant classes showed that tricyclic antidepressants reduced suicide and non-suicide mortality; selective serotonin reuptake inhibitors and atypical agents reduced suicide risk, whilst serotonin noradrenaline reuptake inhibitors reduced non-suicide-related mortality.<\/jats:p>\n                  <jats:p>Depression and anxiety are associated with more rapid disease progression and increased mortality in Huntington\u2019s disease. In people with Huntington\u2019s disease affected by depression and anxiety, antidepressant initiation slows disease progression and reduces mortality risk, with preliminary evidence of antidepressant class-specific reduction in both suicide and non-suicide mortality risk. This finding warrants further investigation in both Huntington\u2019s disease and other neurodegenerative diseases.<\/jats:p>","DOI":"10.1093\/brain\/awag009","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T12:44:22Z","timestamp":1767876262000},"page":"2680-2688","source":"Crossref","is-referenced-by-count":0,"title":["Exploring the association between antidepressants, progression and mortality in Huntington\u2019s disease"],"prefix":"10.1093","volume":"149","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5356-5019","authenticated-orcid":false,"given":"Duncan","family":"McLauchlan","sequence":"first","affiliation":[{"name":"Centre for Neuropsychiatric Genetics and Genomics, Division of Psychological Medicine and Clinical Neurosciences, School of Medicine, Cardiff University , Cardiff CF24 4HQ ,","place":["UK"]},{"name":"Department of Neurology, University Hospital Wales , Cardiff CF14 4XW ,","place":["UK"]},{"name":"Advanced NeuroTherapies Centre , Hadyn Ellis Building, Cardiff CF24 4HQ ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheney","family":"Drew","sequence":"additional","affiliation":[{"name":"Centre for Trials Research, Cardiff University , Cardiff CF14 4YS ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Holmans","sequence":"additional","affiliation":[{"name":"Centre for Neuropsychiatric Genetics and Genomics, Division of Psychological Medicine and Clinical Neurosciences, School of Medicine, Cardiff University , Cardiff CF24 4HQ ,","place":["UK"]},{"name":"UK Dementia Research Institute at Cardiff University , Cardiff CF24 4HQ ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Rosser","sequence":"additional","affiliation":[{"name":"Centre for Neuropsychiatric Genetics and Genomics, Division of Psychological Medicine and Clinical Neurosciences, School of Medicine, Cardiff University , Cardiff CF24 4HQ ,","place":["UK"]},{"name":"Advanced NeuroTherapies Centre , Hadyn Ellis Building, Cardiff CF24 4HQ ,","place":["UK"]},{"name":"UK Dementia Research Institute at Cardiff University , Cardiff CF24 4HQ ,","place":["UK"]},{"name":"Cardiff Brain Repair Group, School of Biosciences, Cardiff University , Cardiff CF10 3AX ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,1,21]]},"reference":[{"key":"2026080312465862600_awag009-B1","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/ene.13413","article-title":"Huntington\u2019s disease: A clinical review","volume":"25","author":"McColgan","year":"2018","journal-title":"Eur J Neurol"},{"key":"2026080312465862600_awag009-B2","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1136\/jnnp-2013-307343","article-title":"Neuropsychiatric symptoms in a European Huntington\u2019s disease cohort (REGISTRY)","volume":"85","author":"van Duijn","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2026080312465862600_awag009-B3","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/mds.22412","article-title":"Health-related quality of life in Huntington\u2019s disease: Which factors matter most?","volume":"24","author":"Ho","year":"2009","journal-title":"Mov Disord"},{"key":"2026080312465862600_awag009-B4","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.parkreldis.2022.11.004","article-title":"Psychotropic medication use in Huntington\u2019s disease: A retrospective cohort study","volume":"105","author":"Andriessen","year":"2022","journal-title":"Parkinsonism Relat Disord"},{"key":"2026080312465862600_awag009-B5","first-page":"CD003944","article-title":"Antidepressants for treating depression in dementia","volume":"8","author":"Dudas","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"2026080312465862600_awag009-B6","doi-asserted-by":"crossref","first-page":"298","DOI":"10.5498\/wjp.v12.i2.298","article-title":"Associated mortality risk of atypical antipsychotic medication in individuals with dementia","volume":"12","author":"Phiri","year":"2022","journal-title":"World J Psychiatry"},{"key":"2026080312465862600_awag009-B7","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.parkreldis.2021.01.010","article-title":"Estimating the causal effects of modifiable, non-genetic factors on Huntington disease progression using propensity score weighting","volume":"83","author":"Griffin","year":"2021","journal-title":"Parkinsonism Relat Disord"},{"key":"2026080312465862600_awag009-B8","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/mdc3.12388","article-title":"Data analytics from Enroll-HD, a global clinical research platform for Huntington\u2019s disease","volume":"4","author":"Landwehrmeyer","year":"2016","journal-title":"Mov Disord Clin Pract"},{"key":"2026080312465862600_awag009-B9","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/mds.22837","article-title":"Validation of self-report depression rating scales in Huntington\u2019s disease","volume":"25","author":"de Sousa","year":"2010","journal-title":"Mov Disord"},{"key":"2026080312465862600_awag009-B10","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1176\/appi.neuropsych.13070169","article-title":"Reliability and factor structure of the short problem behaviors assessment for Huntington\u2019s disease (PBA-s) in the TRACK-HD and REGISTRY studies","volume":"27","author":"Callaghan","year":"2015","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"2026080312465862600_awag009-B11","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1212\/WNL.0000000000004743","article-title":"Motor, cognitive, and functional declines contribute to a single progressive factor in early HD","volume":"89","author":"Schobel","year":"2017","journal-title":"Neurology"},{"key":"2026080312465862600_awag009-B12","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/mds.870110204","article-title":"Unified Huntington\u2019s disease rating scale: Reliability and consistency. Huntington study group","volume":"11","author":"Huntington Study Group","year":"1996","journal-title":"Mov Disord"},{"key":"2026080312465862600_awag009-B13","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1093\/aje\/kwq439","article-title":"Doubly robust estimation of causal effects","volume":"173","author":"Funk","year":"2011","journal-title":"Am J Epidemiol"},{"key":"2026080312465862600_awag009-B14","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s40471-022-00308-6","article-title":"Sensitivity analyses for unmeasured confounders","volume":"9","author":"D\u2019Agostino McGowan","year":"2022","journal-title":"Curr Epidemiol Rep"},{"key":"2026080312465862600_awag009-B15","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2026080312465862600_awag009-B16","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"key":"2026080312465862600_awag009-B17","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1097\/MLR.0000000000001922","article-title":"A tutorial for propensity score weighting for moderation analysis with categorical variables: An application examining smoking disparities among sexual minority adults","volume":"61","author":"Griffin","year":"2023","journal-title":"Med Care"},{"key":"2026080312465862600_awag009-B18","doi-asserted-by":"publisher","author":"McLauchlan","DOI":"10.1101\/2025.08.01.25332817"},{"key":"2026080312465862600_awag009-B19","doi-asserted-by":"crossref","first-page":"111023","DOI":"10.1016\/j.jpsychores.2022.111023","article-title":"The effects of antidepressants on depressive symptoms in manifest Huntington\u2019s disease","volume":"162","author":"Ogilvie","year":"2022","journal-title":"J Psychosom Res"},{"key":"2026080312465862600_awag009-B20","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1001\/jamainternmed.2014.7663","article-title":"Cumulative use of strong anticholinergics and incident dementia: A prospective cohort study","volume":"175","author":"Gray","year":"2015","journal-title":"JAMA Intern Med"},{"key":"2026080312465862600_awag009-B21","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/WAD.0000000000000103","article-title":"Antidepressant use in the elderly is associated with an increased risk of dementia","volume":"30","author":"Wang","year":"2016","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"2026080312465862600_awag009-B22","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1002\/alz.13807","article-title":"Antidepressant use in relation to dementia risk, cognitive decline, and brain atrophy","volume":"20","author":"vom Hofe","year":"2024","journal-title":"Alzheimers Dement"},{"key":"2026080312465862600_awag009-B23","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1136\/jnnp.2008.152983","article-title":"Use of antidepressants and the risk of Parkinson\u2019s disease: A prospective study","volume":"80","author":"Alonso","year":"2009","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2026080312465862600_awag009-B24","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.nbd.2017.07.007","article-title":"Nortriptyline inhibits aggregation and neurotoxicity of alpha-synuclein by enhancing reconfiguration of the monomeric form","volume":"106","author":"Collier","year":"2017","journal-title":"Neurobiol Dis"},{"key":"2026080312465862600_awag009-B25","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1186\/s12883-022-02988-5","article-title":"Antidepressants trial in Parkinson\u2019s disease (ADepT-PD): Protocol for a randomised placebo-controlled trial on the effectiveness of escitalopram and nortriptyline on depressive symptoms in Parkinson\u2019s disease","volume":"22","author":"Schrag","year":"2022","journal-title":"BMC Neurol"},{"key":"2026080312465862600_awag009-B26","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1176\/appi.neuropsych.20230120","article-title":"Treatment of depression in Huntington\u2019s disease: A systematic review","volume":"36","author":"Zadegan","year":"2024","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"2026080312465862600_awag009-B27","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/mp.2011.125","article-title":"Genome-wide association study of Alzheimer\u2019s disease with psychotic symptoms","volume":"17","author":"Hollingworth","year":"2012","journal-title":"Mol Psychiatry"},{"key":"2026080312465862600_awag009-B28","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.biopsych.2019.12.010","article-title":"Genetic risk underlying psychiatric and cognitive symptoms in Huntington\u2019s disease","volume":"87","author":"Ellis","year":"2020","journal-title":"Biol Psychiatry"},{"key":"2026080312465862600_awag009-B29","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1111\/j.1460-9568.2005.04365.x","article-title":"Cognitive disorders and neurogenesis deficits in Huntington\u2019s disease mice are rescued by fluoxetine","volume":"22","author":"Grote","year":"2005","journal-title":"Eur J Neurosci"},{"key":"2026080312465862600_awag009-B30","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/jne.12255","article-title":"Hypothalamic-pituitary-adrenal axis functioning in Huntington\u2019s disease and its association with depressive symptoms and suicidality","volume":"27","author":"Hubers","year":"2015","journal-title":"J Neuroendocrinol"},{"key":"2026080312465862600_awag009-B31","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.biopsych.2009.03.015","article-title":"Inflammation causes mood changes through alterations in subgenual cingulate activity and mesolimbic connectivity","volume":"66","author":"Harrison","year":"2009","journal-title":"Biol Psychiatry"},{"key":"2026080312465862600_awag009-B32","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S1474-4422(23)00454-4","article-title":"Safety and efficacy of laquinimod for Huntington\u2019s disease (LEGATO-HD): A multicentre, randomised, double-blind, placebo-controlled, phase 2 study","volume":"23","author":"Reilmann","year":"2024","journal-title":"Lancet Neurol"},{"key":"2026080312465862600_awag009-B33","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s12916-025-03851-3","article-title":"Antidepressant use and cognitive decline in patients with dementia: A national cohort study","volume":"23","author":"Mo","year":"2025","journal-title":"BMC Med"},{"key":"2026080312465862600_awag009-B34","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1001\/jamapsychiatry.2014.3018","article-title":"Antipsychotics, other psychotropics, and the risk of death in patients with dementia: Number needed to harm","volume":"72","author":"Maust","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"2026080312465862600_awag009-B35","doi-asserted-by":"crossref","first-page":"2040622319853719","DOI":"10.1177\/2040622319853719","article-title":"Antidepressant treatment and mortality risk in patients with dementia and depression: A nationwide population cohort study in Taiwan","volume":"10","author":"Su","year":"2019","journal-title":"Ther Adv Chronic Dis"},{"key":"2026080312465862600_awag009-B36","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/acps.12630","article-title":"Antidepressants and mortality risk in a dementia cohort: Data from SveDem, the Swedish dementia registry","volume":"134","author":"Enache","year":"2016","journal-title":"Acta Psychiatr Scand"},{"key":"2026080312465862600_awag009-B37","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.2147\/NDT.S325521","article-title":"Impact of antidepressants on cardiac events and all-cause mortality in Parkinson\u2019s disease: A national data-linkage study","volume":"17","author":"Orayj","year":"2021","journal-title":"Neuropsychiatr Dis Treat"},{"key":"2026080312465862600_awag009-B38","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.parkreldis.2014.07.012","article-title":"Increased all-cause mortality with psychotropic medication in Parkinson\u2019s disease and controls: A national register-based study","volume":"20","author":"Frandsen","year":"2014","journal-title":"Parkinsonism Relat Disord"},{"key":"2026080312465862600_awag009-B39","doi-asserted-by":"crossref","first-page":"fcac278","DOI":"10.1093\/braincomms\/fcac278","article-title":"Different depression: Motivational anhedonia governs antidepressant efficacy in Huntington\u2019s disease","volume":"4","author":"McLauchlan","year":"2022","journal-title":"Brain Commun"},{"key":"2026080312465862600_awag009-B40","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1002\/mds.24978","article-title":"Tricyclic antidepressants delay the need for dopaminergic therapy in early Parkinson\u2019s disease","volume":"27","author":"Paumier","year":"2012","journal-title":"Mov Disord"},{"key":"2026080312465862600_awag009-B41","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1002\/sim.2053","article-title":"The use of the propensity score for estimating treatment effects: Administrative versus clinical data","volume":"24","author":"Austin","year":"2005","journal-title":"Stat Med"},{"key":"2026080312465862600_awag009-B42","doi-asserted-by":"crossref","first-page":"e070717","DOI":"10.1136\/bmj-2022-070717","article-title":"Emulating the GRADE trial using real world data: Retrospective comparative effectiveness study","volume":"379","author":"Deng","year":"2022","journal-title":"BMJ"},{"key":"2026080312465862600_awag009-B43","doi-asserted-by":"crossref","first-page":"e069400","DOI":"10.1136\/bmj-2021-069400","article-title":"Agreement of treatment effects from observational studies and randomized controlled trials evaluating hydroxychloroquine, lopinavir-ritonavir, or dexamethasone for COVID-19: Meta-epidemiological study","volume":"377","author":"Moneer","year":"2022","journal-title":"BMJ"},{"key":"2026080312465862600_awag009-B44","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1212\/WNL.0b013e318294b304","article-title":"Characterization of the Huntington intermediate CAG repeat expansion phenotype in PHAROS","volume":"80","author":"Killoran","year":"2013","journal-title":"Neurology"}],"container-title":["Brain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/brain\/advance-article-pdf\/doi\/10.1093\/brain\/awag009\/66506676\/awag009.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/brain\/article-pdf\/149\/8\/2680\/66506676\/awag009.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/brain\/article-pdf\/149\/8\/2680\/66506676\/awag009.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T16:47:12Z","timestamp":1785775632000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/brain\/article\/149\/8\/2680\/8434666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,21]]},"references-count":44,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,1,21]]},"published-print":{"date-parts":[[2026,8,3]]}},"URL":"https:\/\/doi.org\/10.1093\/brain\/awag009","relation":{},"ISSN":["0006-8950","1460-2156"],"issn-type":[{"value":"0006-8950","type":"print"},{"value":"1460-2156","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,1,21]]}}}